Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Diabetes
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Diabetes
    TopAbstracts in Diabetes 12/01/2009 - (DGNews)
    Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function - (N Engl J Med)
    TopAbstracts in Diabetes 11/24/2009 - (DGNews)
    TopAbstracts in Diabetes 11/17/2009 - (DGNews)
    Darbepoetin Alfa Risky for Type 2 Diabetics With Kidney Disease: Presented at AHA - (DGDispatch)

    News archive

     Recent webcasts/CME - Diabetes
      Clinical Practice In Type 2 Diabetes: After Metformin And Lifestyle, Then What?
      Diabetes and the Heart: Diabetes and Glycemic Control - Endocrine
      Medication Use for Diabetes, Hypertension, and Hypercholesterolemia from 1988-1994 to 2001-2006
      Diabetes and the Heart: Cardiometabolic Screening and Hospital Care
      Diabetes and the Heart: Diabetes and Glycemic Control - Cardiovascular

      Webcasts/CME archive

       Recent cases - Diabetes
        Transient Anti-GAD Antibody Positivity and Acute Pancreatitis with Pancreas Tail Swelling in a Patient with Susceptible Haplotype for Type 1 Diabetes Mellitus
        Acquired Perforating Dermatosis: Association with Diabetes and Renal Failure
        A Patient Presenting with Symptomatic Hypomagnesemia Caused by Metformin-Induced Diarrhoea: A Case Report
        Absence of Diabetic Retinopathy in a Patient who has had Diabetes Mellitus for 69 Years, and Inadequate Glycemic Control: Case Report
        Gallbladder Edema in Type 1 Diabetic Patient due to Delayed-type Insulin Allergy

        Cases archive
          




        my personal edition > diabetes > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Gemfibrozil Increases Plasma Concentrations of Rosiglitazone

        A DGReview of :"Gemfibrozil considerably increases the plasma concentrations of rosiglitazone"
        Diabetologia

        09/10/2003
        By Jill Taylor


        ERRATUM: Gemfibrozil Contraindicated in Diabetics Patients Taking Rosiglitazone

        There was an error in the title of a review (Aug. 6, 2003) of a paper in Diabetologia.

        The original title read:
        Gemfibrozil Contraindicated in Diabetics Patients Taking Rosiglitazone

        The corrected text now reads:

        Gemfibrozil Increases Plasma Concentrations of Rosiglitazone

        We apologise to the manufacturer for having published inaccurate information on their product.

        We are committed to providing the most accurate, relevant and balanced information for physicians worldwide and have devoted considerable resources to ensuring this. We deeply regret this error.

        --------------------------------------------------------

        Administration of usual therapeutic doses of gemfibrozil considerably increases the plasma concentrations of rosiglitazone, an insulin-sensitising drug used to treat patients with Type 2 diabetes mellitus.

        Gemfibrozil, a lipid-lowering agent, was recently demonstrated to dangerously increase the plasma concentrations of another antidiabetic drug, repaglinide. Because fibrates are commonly used to lower triglyceride levels in diabetics, M. Niemi and colleagues of the Helsinki University Central Hospital in Finland, investigated a possible interaction between gemfibrozil and rosiglitazone.

        The investigators performed a randomised, placebo-controlled crossover study in which 10 healthy volunteers (9 men, 1 woman) took 600 mg gemfibrozil or placebo orally twice daily for 4 days, and a single 4 mg dose of rosiglitazone on day 3.

        Day 3 food intake was standardised, and patients received food at 3 hours and 7 hours after rosiglitazone administration. Venous blood samples were collected before and for up to 48 hours after rosiglitazone administration.

        Gemfibrozil was found to raise the mean area under the plasma rosiglitazone concentration-time curve 2.3-fold, as well as increase the elimination half-life from 3.6 to 7.6 hours. Additionally, while gemfibrozil had only a minor effect on peak plasma rosiglitazone concentration (a 1.2-fold increase), the plasma rosiglitazone concentration measured at 24 hours post administration increased almost 10-fold.

        Considerable variability between individuals in the extent of drug interaction was noted, with the relative increase in rosiglitazone concentration ranged from 51 to 179%.

        Concomitant administration of the two drugs may enhance rosiglitazone efficacy, but may also increase the risk of concentration-dependent adverse effects. "Due to the possibility of an increased risk of adverse effects, it could be advisable to avoid co administration of gemfibrozil and rosiglitazone," researchers say.

        The researchers recommend that rosiglitazone dose be reduced by about 50 to 70% if gemfibrozil treatment is started on a patient using rosiglitazone, and the patient carefully monitored for signs and symptoms of adverse effects.
        Diabetologia 2003 Jul 29;[Epub ahead of print]. "Gemfibrozil considerably increases the plasma concentrations of rosiglitazone"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send